Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update

By: via Benzinga
Cellectar Biosciences, Inc. (NASDAQ: CLRB), an oncology-focused biotechnology company, today provides an update on its recently ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.